摘要
目的:观察孟鲁司特治疗咳嗽变异性哮喘(CVA)的临床疗效。方法:78例CVA患儿随机分成两组,对照组常规给予博利康尼、酮替芬口服;观察组在对照组的基础上加用孟鲁司特咀嚼片,至临床症状消失后12周停药。停药后随访6个月观察复发情况。结果:治疗组取得临床缓解所需时间比对照组明显缩短(P<0.01),复发率较对照组明显降低(P<0.01)。结论:孟鲁司特治疗咳嗽变异性哮喘疗效明确且不良反应少。
Objective：To observe the effect of montelukast on the cough variant asthma （CVA）. Methods： 78 cases of CVA were randomly divided into two groups. The control group received not only conventional treatments such as terbutaline and ketotifen. The treatment group received not only conventional ones but also montelukast, The treatment was kept for other 12 weeks after the clinical symptoms disappeared. The same follow-up was done. Results： The remission time of the treatment group was shorter than that of the control group （ P 〈 0.01 ）, and the recurrence rate was lower （ P 〈 0.01 ）. Conclusions： The treatment of cough variant asthma with montelukast was significant and adverse reaction was low.
出处
《儿科药学杂志》
CAS
2006年第4期36-37,共2页
Journal of Pediatric Pharmacy
